THE TAPE
MYGN · Diagnostics · $532.8M

Myriad Genetics Inc

$5.57▼ −1.59%
Last close
Relative strength
94RS
of 99, against every stock▲ +89 on the month
Powering up
Unconfirmed
+52.3%
six months against the S&P 500
52-week range
−31.1%
from the high
$2.74$8.09
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth FLATProof PENDING
Quarter to Sep 30, revenue −2% on a year ago
Why it is on no screen

MYGN is off the screens on one check: shallow enough.

A base has formed14.6 weeks, from 2.74 to 6.43.
Long enough to count14.6 weeks against 3 needed.
Shallow enough57.4% deep against 35% allowed.
Close to its pivot-13.4% from the pivot; listed down to -20%.
Relative strengthRS 94 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
$4.80
-13.8% · tested 3× · last 29 sessions ago
Resistance above
$5.77
+3.6% · tested 4× · last 2 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

Myriad Genetics Inc is not on any of the screens right now. Its relative strength rating is 94, and it sits in Diagnostics.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against the S&P 500
+44.4%
Three months against the S&P 500
+101.3%
Six months against the S&P 500
+52.3%

Its industry has too few members to make an index of, so it is read against the S&P 500 and can only be turning, caution or unconfirmed.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 21.6% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$803.6M
-1.5% year on year
Operating margin
-14.3%
gross 68.3%
Net margin
-16.1%
Free cash flow
$-19.9M
-3.7% of market cap
Price to sales
0.66×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 4
Key takeaway
Margins are improving, but the financial turnaround is not yet proven.
Revenue
$202.7M
+6.3% QoQ · -1.5% YoY
Gross margin
67.9%
+1.3 pts QoQ
Net income
−$43.9M
Loss
Free cash flow
−$6.5M
Burning · 17q runway

What the numbers say

  • Revenue -1.5% year over year, +6.3% on the quarter
  • Good: Gross margin 67.9%, +1.3 points on the quarter
  • Weak: Net loss $44M, wider than $43M last quarter
  • Weak: Burning cash: operating cash flow -$6M, free cash flow -$6M, better than -$8M last quarter · 16 quarters of cash at this burn
  • Net debt $14M · cash $107M
Revenue by quarter
Free cash flow
Net income
shares +2.8% in a year · net debt $14.0M

What is not obvious

  • Weak: Stock compensation $9M added back against negative operating cash flow
  • Weak: Interest $4M a quarter against an operating loss: the debt is carried by the balance sheet, not operations
Final read
Growth: FLAT · Economic proof: PENDING
Key question: Can the recovery in margins reach operating profit and cash?
The next test is operating profit: net loss $44M, wider than $43M last quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 trimmed, 1 sold out.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Reported resultsFiling · 2026-11-11
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Pulled back while its group leadsTape · 2026-11-11
3 lower closes in a leading group, 50d held, at 5.67
Mixed: stocks have lagged random stocks by 1.0% over three sessions, not consistently enough to call (433 cases over 59 nights). Against their own sector they have lagged by 0.9%.
GappedTape · 2026-11-07
-5.9%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Earnings comingEvent · 2026-11-03
reports 2026-11-04 amc
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).
GappedTape · 2026-11-03
-7.9%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Tightening after a sharp runTape · 2026-10-31
range halved after a +60% thrust, at 6.35
No measurable effect: stocks behave like random ones over the next three sessions (887 cases over 60 nights).
GappedTape · 2026-10-29
+5.4%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Tightening after a sharp runTape · 2026-10-28
range halved after a +54% thrust, at 6.29
No measurable effect: stocks behave like random ones over the next three sessions (887 cases over 60 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Myriad Genetics (MYGN) Reports Q3 Loss, Beats Revenue EstimatesZacks Investment Research · 13 days ago

Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.

Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

What analysts expect

No analyst coverage for this company. Most listed names have none, and an absence here is not a judgement about the business.

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Myriad Genetics Inc (MYGN) — The Tape